SK Biopharmaceuticals Co., Ltd.
Research SK Biopharmaceuticals Co., Ltd. (326030.KS) on Bullrun: market cap KRW 5.74T. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker326030.KS
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 5.74T
- Financial periodQ2 2026
- RevenueKRW 247.37B
- Net incomeKRW 85.06B
- Free cash flowKRW 77.24B
- Gross margin93.9%
Valuation Snapshot
latest market cap is KRW 5.74T.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 5.74T | n/a | n/a | n/a |
Dividend history
About SK Biopharmaceuticals Co., Ltd.
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease;
ETFs that hold SK Biopharmaceuticals Co., Ltd.
US-listed ETFs
SK Biopharmaceuticals Co., Ltd. is held by 39 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares MSCI South Korea ETF (EWY) | 0.15% | 0.59% |
| iShares MSCI Emerging Markets ETF (EEM) | 0.01% | 0.72% |
| iShares Core MSCI Emerging Markets ETF (IEMG) | 0.01% | 0.09% |
| Vanguard FTSE Developed Markets Index Fund ETF Shares (VEA) | 0.01% | 0.03% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Schwab International Equity ETF (SCHF) | 0.01% | 0.03% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | 0.01% | 0.04% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SK Biopharmaceuticals Co., Ltd.'s market cap?
SK Biopharmaceuticals Co., Ltd.'s market capitalization is KRW 5.74T.
What does SK Biopharmaceuticals Co., Ltd. do?
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication.